ISCT launches Group of commercial development of cell therapy for peripheral vascular disease.

Vancouver, January of 2011. To maintain its commitment to connect industry, regulatory experts, medical societies and translational centres to advance emerging cell therapies, ISCT announces its first group of business development for cell therapies for peripheral vascular disease (PVD).

The PVD is a disease in which the arteries that carry blood to the extremities become narrow or coagulan. In a population of primary care defined by age and common risk factors the prevalence of PVD is about one in three (1). Limb ischemia (CLI) critical is a very serious condition of developing countries in which patients suffering from acute pain and ulcers on the skin which can lead to amputation of the limb. The CLI has a mortality rate of 15-30% at 5 years.(2)

To treat the debilitating disease, ISCT has created a progressive Forum to bring together a panel of experts and facilitate open and in-depth discussion of whether Cellular therapy can meet the needs not covered these patients and how. The focus group will take place in New York, United States. UU., in the present day in partnership with the Cardiovascular Research Foundation, sponsor of the Sixth International Conference on Cell Therapy for Cardiovascular Disease.

“As we enter the era of studies of phase 3 of more than 300 patients, is vital to the research community to identify appropriate endpoints they correlate with positive clinical results,” said Warren Sherman, MD, director of Regenerative Cardiovascular Research at The Jack H. Skirball Center for Cardiovascular Research. “From there, the design of the essay can optimized to evaluate effective clinical and, hopefully, improve outcomes for patients with CLI.” These patients have a very poor prognosis. “Help with cell therapy would be a huge step forward, and would have implications for the patients with vascular of other organ systems.”

Ed Horwitz, M.D. PhD, CEO of ISCT strongly agreed: “the release of this series of focus groups is the latest initiative whereby ISCT is creating alignment with the academia and industry to accelerate the development and maturation of the field and eventually lead cell therapy treatments to patients faster.” “The intention of ISCT is the international field of regenerative medicine and cell therapy can benefit of groups through public open access to the final report and findings published in peer reviewed journals.”

The initiative of the Group ISCT continues ISCT Industry Community successful launch in August 2010. See: ISCT – media.

ISCT welcomes corporate members to the Industry Community by 2011:

sponsors: Aastrom Biosciences Inc., BD Biosciences Inc. BioLife Solutions Inc., Pfizer Regenerative Medicine Pluristem Therapuetics Inc. partners: CaridianBCT Inc., Sartorius Stedim Biotech GmbH., STEMCELL Technologies Inc. supporters: CellGenix GmbH., B.V. Pharmacell, members: Apceth GmbH & Co. Preservation Solutions Inc, Beike Biotechnology Co.Ltd., JIU Biotech Inc., Tengion Inc., STEMSOFT Software Inc., ZMKS International Cancer Therapy Biotechnology Co. Ltd.

The full list of members can be seen on the page of the Community Industry.

ISCT is a global association that promotes the translation of scientific research to provide innovative cell therapies for patients. Established in 1992, their membership and leadership are formed by world medical experts in technology, professional scientists in biotechnology and Pharmacology and experts in regulation around the world focused on aspects preclinical and translational cell therapy product development.

–
References

(1) Hirsch AT et to the. JAMA. 2001; 286: 1317-1324

(2) Hirsch AT et to the. Circulation. 2006; 113:e463 – 654